A Single-Arm, Multicenter Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Registrational
- Acronyms STASEY
- Sponsors Roche
- 31 Jul 2017 Planned End Date changed from 22 Jul 2020 to 12 Aug 2020.
- 31 Jul 2017 Planned primary completion date changed from 22 Jul 2020 to 12 Aug 2020.
- 31 Jul 2017 Planned initiation date changed from 27 Jul 2017 to 11 Aug 2017.